Our cornerstones
Science and innovation drive everything we do

We are committed to delivering innovative, effective and useful medicines based on our formulas and filling unmet medical needs to improve our customers’ quality of life.

SCIENCE

Molecules capable of slowing down or even reversing the biological process that causes hair loss have been used as monotherapies for many years. We’ve taken things a step further and developed a groundbreaking combination of three complementary active molecules that work in perfect synergy to promote hair growth at every step of regrowth.

Innovation

Scientific rigour demands absolute discipline. Nothing can be left to chance. This does not mean that innovation can’t be integrated into processes, research and experimentation. Innovation makes it possible for us to develop models and products and offer ever more effective and targeted solutions to people’s problems. When it comes to the development of critical components of our business and products, innovation is at the heart of our business practices and strategic development!

Our scientific committee

Houfar Sekhavat, MD
Founder
Peter Ford, Pharma D
Co-Founder
Satish Asotra, Ph.D., MBA
Chief Scientific Officer
Our patents

PROTECTING OUR INTELLECTUAL PROPERTY

Triple Hair is continually filing new patents in markets with significant commercial potential as we develop our products through their life cycle.

Recent publications
SCIENTIFIC NEWS
Triple Hair
Science
Triple Hair retains Endoceutics
READ MORE
Triple Hair
Corporate, In the medias, Science
New Possibilities in Hair Loss Prescription Therapies
READ MORE
Triple Hair
Corporate, Science
Triple Hair Group Reports Positive Results from Safety Studies on its Therapy-07 Prescription Drug
READ MORE
Triple Hair
Corporate, Science
Triple Hair Group consolidates its position as industry leader and innovator for its Therapy-07 prescription drug in the U.S.
READ MORE
Triple Hair
Corporate, Science
Triple Hair Group receives Health Canada approval to start Phase III clinical trials on its Therapy-07 prescription drug in Canada
READ MORE
Ask our Chief Scientific Officer your questions
SATISH ASOTRA
Chief Scientific Officer